Transgenomic Adds New Distributors in China and India for its ICEme Kits that Enable Liquid Biopsy Cancer Testing on Existing Platforms
New Life Science Specialists in China and India Have Signed on to Distribute the Multiplexed ICE COLD-PCR-Based Kits that Work with Liquid or Tissue Samples and on All Sequencing Platforms
OMAHA, Neb. — Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced that it has signed agreements with two additional distributors in China and India for its ICEme™ Mutation Enrichment Kits for cancer genomic testing. The kits incorporate Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) technology and are designed to enable virtually any laboratory to conduct high quality DNA mutation detection in cancer patients using plasma, blood or tissue samples and existing sequencing platforms. The new distributors, JoyingBio in China and Biotron Healthcare in India, are important suppliers of advanced life science products in their respective markets.
“Asia represents large and growing healthcare sectors, and our ICEme Kits will allow researchers and clinicians in the rapidly expanding markets of China and India

